Applied Molecular Transport ( ) - 株価, ニュースと分析Nasdaq:AMTI

AMTI 株式概要

Applied Molecular Transport Inc., a clinical-stage biopharmaceutical company, engages in the design and development of a pipeline of oral biologic product candidates to treat autoimmune, inflammatory, metabolic, and other diseases. 詳細

AMTI ファンダメンタル分析
スノーフレーク・スコア
評価	2/6
将来の成長	0/6
過去の実績	0/6
財務の健全性	4/6
配当金	0/6

リスク分析

過去5年間で収益は年間25.6%減少しました。

キャッシュランウェイが1年未満である

収益が 100 万ドル未満 ( $0 )

過去3か月間に大規模なインサイダー売却が発生

+3 さらなるリスク

Applied Molecular Transport Inc. 競合他社

Turnstone Biologics

NasdaqGM:TSBX

US$11.1m

Indaptus Therapeutics

NasdaqCM:INDP

US$10.2m

Apollomics

NasdaqCM:APLM

US$10.1m

Oncotelic Therapeutics

OTCPK:OTLC

US$12.6m

価格と性能

の歴代最高値、変動、値下がりまとめApplied Molecular Transport
過去の株価
現在の株価	US$0.26
52週高値	US$0.84
52週安値	US$0.13
ベータ	2.29
11ヶ月の変化	46.68%
3ヶ月変化	67.52%
1年変化	-26.21%
33年間の変化	-99.15%
5年間の変化	n/a
IPOからの変化	-98.54%

Recent updates

Here's Why We're A Bit Worried About Applied Molecular Transport's (NASDAQ:AMTI) Cash Burn Situation

Mar 07

We're A Little Worried About Applied Molecular Transport's (NASDAQ:AMTI) Cash Burn Rate

Nov 13

Applied Molecular Transport GAAP EPS of -$0.93

Aug 04

Companies Like Applied Molecular Transport (NASDAQ:AMTI) Could Be Quite Risky

Jul 27

Applied Molecular Transport up 4% after hours on ulcerative colitis candidate data

Jul 05

Applied Molecular: Interesting Drug Delivery Approach For The GI Tract

May 03

We're Keeping An Eye On Applied Molecular Transport's (NASDAQ:AMTI) Cash Burn Rate

Apr 28

We're Hopeful That Applied Molecular Transport (NASDAQ:AMTI) Will Use Its Cash Wisely

Jan 08

We're Hopeful That Applied Molecular Transport (NASDAQ:AMTI) Will Use Its Cash Wisely

Aug 29

Applied Molecular Transport (NASDAQ:AMTI) Is In A Good Position To Deliver On Growth Plans

Apr 05

Have Insiders Been Buying Applied Molecular Transport Inc. (NASDAQ:AMTI) Shares This Year?

Feb 11

Here's Why We're Not Too Worried About Applied Molecular Transport's (NASDAQ:AMTI) Cash Burn Situation

Dec 21

Applied Molecular Transport reports Q3 results

Nov 12

株主還元

	AMTI	US Biotechs	US 市場
7D	-11.0%	2.5%	2.2%
1Y	-26.2%	16.1%	31.6%

業界別リターン: AMTI過去 1 年間で16.1 % の収益を上げたUS Biotechs業界を下回りました。

リターン対市場: AMTIは、過去 1 年間で31.6 % のリターンを上げたUS市場を下回りました。

価格変動

Is AMTI's price volatile compared to industry and market?
AMTI volatility
AMTI Average Weekly Movement	13.5%
Biotechs Industry Average Movement	9.8%
Market Average Movement	6.3%
10% most volatile stocks in US Market	15.7%
10% least volatile stocks in US Market	3.1%

安定した株価: AMTIの株価は過去 3 か月間にわたって変動しています。

時間の経過による変動: AMTIの weekly volatility ( 13% ) は過去 1 年間安定していますが、依然としてUSの株式の 75% よりも高くなっています。

会社概要

設立	従業員	CEO（最高経営責任者	ウェブサイト
2010	13	Shawn Cross	www.appliedmt.com

Applied Molecular Transport Inc. 基礎のまとめ

Applied Molecular Transport の収益と売上を時価総額と比較するとどうか。
AMTI 基礎統計学
時価総額	US$10.87m
収益（TTM）	-US$74.79m
売上高(TTM)	n/a

0.0x

P/Sレシオ

-0.1x

PER（株価収益率

AMTI は割高か？

公正価値と評価分析を参照

収益と収入

最新の決算報告書（TTM）に基づく主な収益性統計
AMTI 損益計算書（TTM）
収益	US$0
売上原価	US$42.08m
売上総利益	-US$42.07m
その他の費用	US$32.71m
収益	-US$74.79m

直近の収益報告

Sep 30, 2023

次回決算日

該当なし

一株当たり利益（EPS）	-1.81
グロス・マージン	0.00%
純利益率	0.00%
有利子負債／自己資本比率	0%

AMTI の長期的なパフォーマンスは？

過去の実績と比較を見る

AMTI 株式概要

リスク分析

Applied Molecular Transport Inc. 競合他社

NasdaqGM:TSBX

US$11.1m

NasdaqCM:INDP

US$10.2m

NasdaqCM:APLM

US$10.1m

OTCPK:OTLC

US$12.6m

価格と性能

最新ニュース

Applied Molecular Transport Files Form 15

Applied Molecular Transport Inc.(NasdaqCM:AMTI) dropped from NASDAQ Composite Index

Cyclo Therapeutics, Inc. (NasdaqCM:CYTH) completed the acquisition of Applied Molecular Transport Inc. (NasdaqCM:AMTI) from a group of shareholders for $10.2 million.

New minor risk - Shareholder dilution

Cyclo Therapeutics, Inc. (NasdaqCM:CYTH) entered into a definitive agreement to acquire Applied Molecular Transport Inc. (NasdaqCM:AMTI) for $11.9 million.

Cyclo Therapeutics, Inc. (NasdaqCM:CYTH) entered into a definitive agreement to acquire Applied Molecular Transport Inc. (NasdaqCM:AMTI) for $11.9 million.

Recent updates

Applied Molecular Transport Files Form 15

Applied Molecular Transport Inc.(NasdaqCM:AMTI) dropped from NASDAQ Composite Index

Cyclo Therapeutics, Inc. (NasdaqCM:CYTH) completed the acquisition of Applied Molecular Transport Inc. (NasdaqCM:AMTI) from a group of shareholders for $10.2 million.

New minor risk - Shareholder dilution

Cyclo Therapeutics, Inc. (NasdaqCM:CYTH) entered into a definitive agreement to acquire Applied Molecular Transport Inc. (NasdaqCM:AMTI) for $11.9 million.

Cyclo Therapeutics, Inc. (NasdaqCM:CYTH) entered into a definitive agreement to acquire Applied Molecular Transport Inc. (NasdaqCM:AMTI) for $11.9 million.

New major risk - Market cap size

Applied Molecular Receives Letter from Nasdaq Regarding Listing Rule 5100

New major risk - Revenue and earnings growth

New major risk - Market cap size

Applied Molecular Transport Inc. Announces Executive Changes

Price target decreased by 39% to US$0.90

Here's Why We're A Bit Worried About Applied Molecular Transport's (NASDAQ:AMTI) Cash Burn Situation

Applied Molecular Transport Receives Non-Compliance Notice From Nasdaq

Applied Molecular Transport Inc. Announces Resignation of Randall Mrsny from the Board of Directors

Applied Molecular Transport Inc. Announces Top-line Phase 2 Results from LOMBARD Monotherapy Trial of Oral AMT-101 in Patients with Moderate-to-Severe Ulcerative Colitis

Independent Director recently bought US$150k worth of stock

Price target increased to US$13.67

We're A Little Worried About Applied Molecular Transport's (NASDAQ:AMTI) Cash Burn Rate

Applied Molecular Transport Completes Enrollment of Phase 2 Lombard Monotherapy Trial of Oral Amt-101 in Patients with Moderate-To-Severe Ulcerative Colitis

Forecast to breakeven in 2024

Applied Molecular Transport GAAP EPS of -$0.93

Companies Like Applied Molecular Transport (NASDAQ:AMTI) Could Be Quite Risky

Applied Molecular Transport Announces Top-Line Phase 2 Results from Market Combination Trial of Oral AMT-101 in Patients with Moderate-To-Severe Ulcerative Colitis

Applied Molecular Transport up 4% after hours on ulcerative colitis candidate data

Applied Molecular Transport Inc.(NasdaqGS:AMTI) dropped from Russell 2000 Growth Index

Independent Director recently bought US$211k worth of stock

Insider recently bought US$306k worth of stock

Price target decreased to US$54.08

Applied Molecular: Interesting Drug Delivery Approach For The GI Tract

We're Keeping An Eye On Applied Molecular Transport's (NASDAQ:AMTI) Cash Burn Rate

Applied Molecular Transport to Report Top-Line Phase 2 Results from FILLMORE Trial of Oral AMT-101 in Patients with Chronic Pouchitis

Price target decreased to US$58.28

Applied Molecular Transport Inc., Annual General Meeting, May 24, 2022

Applied Molecular Transport Inc. Appoints Charlene Banard to Its Board of Directors

Price target decreased to US$69.00

Independent Director recently bought US$318k worth of stock

Less than half of directors are independent

Applied Molecular Transport Inc. Announces Management Changes

We're Hopeful That Applied Molecular Transport (NASDAQ:AMTI) Will Use Its Cash Wisely

Chief Medical Officer exercised options to buy US$458k worth of stock.

Co-Founder recently bought US$52k worth of stock

Insider recently bought US$250k worth of stock

We're Hopeful That Applied Molecular Transport (NASDAQ:AMTI) Will Use Its Cash Wisely

Chief Financial Officer exercised options and sold US$255k worth of stock

Chief Business & Strategy Officer exercised options and sold US$289k worth of stock

Independent Chairman recently sold US$8.7m worth of stock

Applied Molecular Transport Inc.(NasdaqGS:AMTI) dropped from Russell 2500 Value Index

Chief Medical Officer exercised options and sold US$393k worth of stock

Applied Molecular Transport (NASDAQ:AMTI) Is In A Good Position To Deliver On Growth Plans

Applied Molecular Transport Expands Clinical Pipeline and Announces First Subject Dosed in Phase 1a Trial of Oral AMT-126

New 90-day high: US$64.47

Applied Molecular Transport Inc. Enter into a Lease Agreement with Are-East Jamie Court, LLC

Have Insiders Been Buying Applied Molecular Transport Inc. (NASDAQ:AMTI) Shares This Year?

New 90-day high: US$39.85

Applied Molecular Transport Inc. Appoints Douglas Rich as Chief Technical Officer

New 90-day high: US$34.38

Here's Why We're Not Too Worried About Applied Molecular Transport's (NASDAQ:AMTI) Cash Burn Situation

Applied Molecular Transport reports Q3 results

Applied Molecular Transport Announces Publication of Preclinical Data Demonstrating Potential of Novel Oral Il-10 Biologic Therapeutic (Amt-101) for Inflammatory Diseases in the Journal of Immunology